Canada’s Federal Court of Appeal has dismissed an attempt by Pfizer to limit damages owed to Pharmascience as part of long-running litigation over Lyrica (pregabalin). The court rejected Pfizer’s argument that the generics firm was not entitled to certain damages for lost sales that Pfizer said could have been blocked by the originator hypothetically seeking to enforce a Lyrica patent, in a ruling that helps to clarify the country’s section 8 damages rules.
Pharmascience had originally attempted to enter Canada’s pregabalin market in 2011, but was barred from doing so by Pfizer having...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?